Antoine Yver, MD, MSc, has been appointed global head, Oncology Research and Development, Daiichi Sankyo, Inc. In this newly created role, Dr. Yver will have responsibility for leading all global R&D across the oncology therapeutic area including external investments, internal pipeline decisions, and resourcing requirements. He reports to Glenn Gormley, MD, Ph.D., senior executive officer and global head, R&D, Daiichi Sankyo Co., Ltd. and chairman of the board and president, Daiichi Sankyo, Inc.
 
Dr. Yver joins the company from AstraZeneca, where he most recently served as senior vice president and head of Oncology, Global Medicines Development, and Global Medicines Development China Lead across all therapeutic areas. Prior to joining AstraZeneca in 2009, he held several international oncology drug development positions at Merck/Schering-Plough, Johnson & Johnson and Rhône-Poulenc Rorer/Aventis.
 
“Antoine brings a strong track record of extensive scientific leadership in many facets of global oncology pharmaceutical research and development along with tremendous passion for science and patients,” said Dr. Gormley. “We are confident that Antoine will provide great leadership and strategic insights in this new role, which underscores Daiichi Sankyo’s commitment to the fight against cancer.”